Pliant Therapeutics Inc (PLRX)
12.85
-0.92
(-6.68%)
USD |
NASDAQ |
Nov 14, 16:00
12.85
0.00 (0.00%)
After-Hours: 20:00
Pliant Therapeutics Enterprise Value: 463.58M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 463.58M |
| November 12, 2024 | 466.62M |
| November 11, 2024 | 508.61M |
| November 08, 2024 | 538.43M |
| November 07, 2024 | 549.99M |
| November 06, 2024 | 581.03M |
| November 05, 2024 | 532.34M |
| November 04, 2024 | 507.39M |
| November 01, 2024 | 509.22M |
| October 31, 2024 | 481.78M |
| October 30, 2024 | 502.47M |
| October 29, 2024 | 521.33M |
| October 28, 2024 | 529.85M |
| October 25, 2024 | 486.65M |
| October 24, 2024 | 458.05M |
| October 23, 2024 | 490.30M |
| October 22, 2024 | 515.85M |
| October 21, 2024 | 517.68M |
| October 18, 2024 | 550.54M |
| October 17, 2024 | 518.29M |
| October 16, 2024 | 545.67M |
| October 15, 2024 | 477.52M |
| October 14, 2024 | 461.09M |
| October 11, 2024 | 456.22M |
| October 10, 2024 | 331.48M |
| Date | Value |
|---|---|
| October 09, 2024 | 324.18M |
| October 08, 2024 | 309.57M |
| October 07, 2024 | 302.27M |
| October 04, 2024 | 327.22M |
| October 03, 2024 | 302.27M |
| October 02, 2024 | 289.49M |
| October 01, 2024 | 267.59M |
| September 30, 2024 | 307.75M |
| September 27, 2024 | 281.13M |
| September 26, 2024 | 272.61M |
| September 25, 2024 | 282.34M |
| September 24, 2024 | 282.34M |
| September 23, 2024 | 281.73M |
| September 20, 2024 | 331.59M |
| September 19, 2024 | 360.78M |
| September 18, 2024 | 353.48M |
| September 17, 2024 | 359.56M |
| September 16, 2024 | 315.18M |
| September 13, 2024 | 323.08M |
| September 12, 2024 | 313.35M |
| September 11, 2024 | 338.89M |
| September 10, 2024 | 382.67M |
| September 09, 2024 | 376.58M |
| September 06, 2024 | 375.98M |
| September 05, 2024 | 405.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-29.62M
Minimum
May 11 2022
1.729B
Maximum
Jan 31 2023
564.27M
Average
528.31M
Median
Enterprise Value Benchmarks
| Haemonetics Corp | 5.535B |
| Marker Therapeutics Inc | 24.68M |
| Aligos Therapeutics Inc | -5.137M |
| Korro Bio Inc | 354.09M |
| CEL-SCI Corp | 38.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.76M |
| Total Expenses (Quarterly) | 62.01M |
| EPS Diluted (Quarterly) | -0.95 |
| Earnings Yield | -25.99% |
| Normalized Earnings Yield | -21.32 |